Teva Pharmaceutical Industries (TEVA)
(Real Time Quote from BATS)
$18.57 USD
+0.56 (3.11%)
Updated Aug 15, 2024 09:52 AM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Teva Pharmaceutical Industries Ltd. [TEVA]
Reports for Purchase
Showing records 421 - 440 ( 460 total )
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Slew of new product launches likely to drive overall strong performance in CY12
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Slew of new product launches likely to drive overall strong performance in CY12..
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Company: Teva Pharmaceutical Industries Ltd.
Industry: Medical - Generic Drugs
Near-term outlook remains bleak due to lack of FTF launches & delay in launch of an ?undisclosed product?...
Provider: FIRST GLOBAL
Analyst: THOMAS K